Quality of Recovery Following Opioids Free Anaesthesia in Laparoscopic Sleeve Gastrectomy

NCT ID: NCT04285255

Last Updated: 2021-11-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

103 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-01

Study Completion Date

2020-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Laparoscopic sleeve gastrectomy is widely employed nowadays. Multimodal analgesia approach is implemented within the enhanced recovery protocol in our facility to improve participants' recovery. Due to side effects of narcotics, the may adversely affect the quality of recovery, the investigators intended to test the efficacy of opioids free anaesthesia on the quality of recovery and postoperative narcotic use.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Narcotics Recovery Quality Analgesia Bariatric Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors
only the anaesthetist is one aware of the study groups

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Opioids anesthesia

received propofol-fentanyl induction of anaesthesia plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side

Group Type ACTIVE_COMPARATOR

Fentanyl

Intervention Type DRUG

opioids anaesthesia

Oblique subcostal transversus abdominis plane block

Intervention Type PROCEDURE

Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane

OFA

received preinduction with dexmeditomidine 0.1µg.kg-1 over 10 min. Induction with propofol 1.5 mg.kg-1-ketamine (ketofol 3:1 mixture) induction plus maintenance mixture of dexmedetomidine 0.5µg.kg-1.h-1, ketamine 0.5mg.kg-1.h-1, and lidocaine 1 mg.kg-1.h-1 plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side

Group Type ACTIVE_COMPARATOR

Ketamine

Intervention Type DRUG

ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia

Dexmedetomidine Injection [Precedex]

Intervention Type DRUG

alpha 2 agonist with sedative, analgesic effect

Oblique subcostal transversus abdominis plane block

Intervention Type PROCEDURE

Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane

Lidocaine

Intervention Type DRUG

infusion of lidocaine 2%(1mg/kg/h)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fentanyl

opioids anaesthesia

Intervention Type DRUG

Ketamine

ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia

Intervention Type DRUG

Dexmedetomidine Injection [Precedex]

alpha 2 agonist with sedative, analgesic effect

Intervention Type DRUG

Oblique subcostal transversus abdominis plane block

Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane

Intervention Type PROCEDURE

Lidocaine

infusion of lidocaine 2%(1mg/kg/h)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 70 ASA II - III adult patients (18-60 years old)
* Elective laparoscopic bariatric surgery.
* Body mass index (BMI) is from 40 to 60
* Trocar sites at or above the umbilicus (T 10 dermatome).

Exclusion Criteria

* Allergy to amino-amide local anaesthetics,
* presence of coagulopathy
* local skin infection at injection sites,
* preoperative chronic dependence upon opioid and NSAID medications,
* liver or renal insufficiency,
* history of psychiatric or neurological disease, deafness,
* previous open surgery,
* patients who need to be converted to open surgery with more tissue trauma,
* ASA (American society of anesthesiologists) class above III were excluded.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Al Mashfa Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Al Mashfa medical center

Khobar, Eastern Provence, Saudi Arabia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Saudi Arabia

References

Explore related publications, articles, or registry entries linked to this study.

Ibrahim M, Elnabtity AM, Hegab A, Alnujaidi OA, El Sanea O. Combined opioid free and loco-regional anaesthesia enhances the quality of recovery in sleeve gastrectomy done under ERAS protocol: a randomized controlled trial. BMC Anesthesiol. 2022 Jan 21;22(1):29. doi: 10.1186/s12871-021-01561-w.

Reference Type DERIVED
PMID: 35062872 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OFA

Identifier Type: -

Identifier Source: org_study_id